Prism TPO Surpasses $1.2 Billion in Oncology Drug Spend Across Expanding Network of Independent Practices

Prism Transparent Purchasing Organization (Prism TPO) is proud to announce that it now represents more than $1.2 billion in annual oncology drug spend across 16 leading independent community oncology practices nationwide. As the first and only transparent purchasing organization built for independent oncology, Prism TPO is redefining how practices purchase drugs by delivering fairness, trust, and competitive pricing. Its mission is to create long-term alignment and sustainability for oncology practices nationwide.

“Crossing the $1 billion threshold across 16 customers—and growing—is a powerful signal that independent practices are ready for a better model,” said Tesh Khullar, Founder & CEO of Prism TPO. “As the fastest-growing GPO in the country, we’ve built a solution that combines purchasing power with true transparency and industry-aligned incentives. We’re excited to continue expanding this new standard for practices nationwide.”

In parallel with this growth, Prism TPO has established 18 pharma partnerships, ensuring that participating practices have access to additional, clearly defined savings opportunities—further enhancing affordability and alignment with value-based care goals.

"This milestone reflects more than market momentum—it underscores the operational discipline and financial transparency we’ve built into the Prism model,” said John Rubino, Vice President of Finance & GPO Operations. “Our ability to deliver clear, unified, and reliable economics to both practices and manufacturers is what sets us apart and drives durable adoption."

Despite their essential role, independent practices have historically operated with limited access to preferred pricing and few opportunities for direct pharma collaboration. Prism TPO addresses these barriers by creating a transparent, efficient framework that enables manufacturers to engage a consolidated network of high-performing community oncology providers—without sacrificing program compliance.

As CEO of Cancer and Blood Specialty Clinic, Dr. Vu Phan leads seven clinics across Orange County and the LA area and has witnessed the mounting pressures that threaten access to affordable, high-quality cancer care.

“Independent oncology practices face constant pressure to deliver high-quality care while managing rising drug costs. Prism TPO’s model brings much-needed clarity, competitive pricing, and alignment with manufacturers—empowering practices like ours to thrive without compromising care.”

Prism TPO’s network includes a growing roster of independent oncology practices, with the following practices already live in its GPO program:

• Birmingham Hematology and Oncology Associates
• Cancer and Blood Specialty Clinic
• Cancer Care Specialists of Illinois
• Cancer Center of Southern California
• Columbus Oncology and Hematology
• Dayton Physicians
• East Texas Hematology and Oncology
• Gabrail Cancer Center
• Gabriel Domenech, M.D.
• Hope and Healing Cancer Services
• NextGen Oncology
• Northwest Medical Specialties
• Nova Oncology
• Sierra Hematology & Oncology Medical Center
• Summit Cancer Centers

Prism TPO is led by a team with deep-rooted experience in both community oncology and the pharmaceutical industry, having dedicated their careers to advancing patient care and improving provider sustainability. Backed by leading venture capital firms such as Obvious Ventures, Prism combines industry expertise with strong strategic support—positioning it to drive meaningful change in how independent oncology practices engage with the drug purchasing landscape.

As a proud partner of the ONCare Alliance, Prism TPO will participate in the upcoming ONCare National Leadership Summit, taking place September 17–20 in Hollywood, Florida. For more information or to connect with the team, visit  PrismTPO.com

Media Contact
Prism TPO
press@prismtpo.com